BIVALIRUDIN IN 0.9% SODIUM CHLORIDE
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Bivalirudin is a direct thrombin inhibitor that binds specifically and reversibly to both free and clot-bound thrombin, inhibiting thrombin-mediated conversion of fibrinogen to fibrin, platelet activation, and clot formation.
| Metabolism | Bivalirudin is not metabolized by cytochrome P450 enzymes; it undergoes proteolytic cleavage and is eliminated by the kidneys, with approximately 20% excreted unchanged in urine. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 20-25% of the administered dose; the remainder undergoes hepatic metabolism and proteolysis, with subsequent renal and biliary elimination of metabolites. Fecal excretion is minimal (<5%). |
| Half-life | The terminal elimination half-life in patients with normal renal function is approximately 25-35 minutes (mean 25 minutes). In patients with moderate-to-severe renal impairment (CrCl <30 mL/min), half-life can be prolonged to 1-3 hours. Clinical context: short half-life allows for rapid reversal upon discontinuation; however, dose adjustment is required in renal impairment. |
| Protein binding | Approximately 20% bound to plasma proteins (primarily albumin). Binding is not saturable at therapeutic concentrations. |
| Volume of Distribution | Volume of distribution at steady state is approximately 0.2-0.3 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding. |
| Bioavailability | Not applicable for intravenous administration (bioavailability is 100% by IV route). No oral bioavailability data; not administered orally. |
| Onset of Action | Intravenous bolus: immediate anticoagulant effect (within 5 minutes). Continuous infusion: steady-state achieved within 15-20 minutes. |
| Duration of Action | After discontinuation of infusion, anticoagulant effect (as measured by activated partial thromboplastin time) returns to baseline within 1-2 hours in patients with normal renal function. Duration is prolonged in renal impairment. |
| Molecular Weight | 2180 Da |
Intravenous bolus of 0.75 mg/kg followed by continuous infusion at 1.75 mg/kg/hour for the duration of percutaneous coronary intervention (PCI). For heparin-induced thrombocytopenia (HIT) patients undergoing PCI, the same dosing is used. For HIT patients without PCI, alternative dosing may be considered.
| Dosage form | SOLUTION |
| Renal impairment | For patients with severe renal impairment (creatinine clearance <30 mL/min) or on hemodialysis, reduce infusion rate to 1.0 mg/kg/hour. No bolus adjustment required. For moderate impairment (CrCl 30-59 mL/min), consider infusion reduction to 1.5 mg/kg/hour. |
| Liver impairment | No specific Child-Pugh based dosing adjustments are available. Bivalirudin is not extensively metabolized by the liver; however, caution is advised in severe hepatic impairment due to potential coagulopathy. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. Use is not recommended unless in clinical trial settings. |
| Geriatric use | Elderly patients (≥65 years) may have reduced renal function; dose adjustment based on creatinine clearance is recommended as per renal adjustment guidelines. No additional specific geriatric dose modifications. |
| 1st trimester | Limited human data; animal studies not sufficient. Use only if clearly needed. |
| 2nd trimester | Limited human data; consider risk-benefit. |
| 3rd trimester | Associated with increased risk of bleeding in mother and neonate; use only if benefit outweighs risk. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Bivalirudin does not cross the placenta in significant amounts due to its high molecular weight and protein binding. |
| Breastfeeding | Not known if excreted in human milk; because many drugs are excreted and potential for serious adverse reactions in nursing infants, discontinue nursing or discontinue drug. |
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | No adequate human data; animal studies show no teratogenic effects. Risk cannot be ruled out. Use only if clearly needed in all trimesters. |
| Fetal Monitoring | Monitor aPTT, ACT, hemoglobin, hematocrit, platelet count, and signs of bleeding. Fetal monitoring with nonstress test or biophysical profile as indicated. |
| Fertility Effects | No human data on fertility effects; animal studies suggest no impact on fertility at therapeutic doses. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | fluid replacement |
| Serious Effects |
Active major bleedingHypersensitivity to bivalirudin or any componentHistory of intracranial hemorrhageSevere uncontrolled hypertension
| Precautions | Hemorrhage: Major bleeding risk, especially in patients with renal impairment (CrCl <30 mL/min) or receiving concomitant antithrombotic therapy, Thrombocytopenia: Monitor platelet counts; bivalirudin can cause immune-mediated thrombocytopenia, Renal impairment: Dose reduction required for moderate to severe renal impairment, Acute stent thrombosis: Risk of acute stent thrombosis in PCI, particularly with certain drug-eluting stents, Hypersensitivity: Serious allergic reactions including anaphylaxis |
| Food/Dietary | No specific food interactions are known with bivalirudin. However, avoid excessive intake of vitamin K-rich foods (e.g., leafy greens) if also on warfarin, though this is not relevant for bivalirudin alone. Maintain a balanced diet and stay hydrated. |
| Clinical Pearls | Bivalirudin is a direct thrombin inhibitor used as an anticoagulant in percutaneous coronary intervention (PCI) and for patients with heparin-induced thrombocytopenia (HIT). It has a short half-life (~25 minutes) and is cleared renally. Monitor activated clotting time (ACT) during PCI; target ACT >300 seconds. Reversal is not required due to rapid offset, but consider hemodialysis if severe bleeding occurs. Avoid in patients with active bleeding or hypersensitivity to the drug. |
| Patient Advice | This medication is given intravenously to prevent blood clots during heart procedures. · You will be monitored closely for signs of bleeding, such as bruising, blood in urine or stool, or bleeding from gums. · Inform your healthcare provider if you have a history of bleeding disorders, recent surgery, or kidney disease. · Do not take other blood thinners (e.g., warfarin, aspirin, NSAIDs) unless prescribed by your doctor. · Seek immediate medical attention if you experience symptoms of allergic reaction (rash, itching, swelling, trouble breathing). |
Loading safety data…